Impacts of Pharmacists-Managed Outpatient Clinic in patients with Hepatitis C virus infection: A Retrospective Study in China

Author:

Huang Can1,Gao Aiping1,Guo Cuixia1,Jia Jinmei1,Zheng Yonghong1,liu wei1

Affiliation:

1. Beijing YouAn Hospital

Abstract

Abstract Objective Pharmacists are health care professionals who are actively involved in identifying and solving drug-related problems (DRPs) in patients with hepatitis C virus (HCV) infection. However, the effectiveness of pharmaceutical services at outpatient clinic for patients with HCV infection have not been reported in China. This study aims to describe and investigate the impacts of pharmacists-managed outpatient clinic in patients with HCV infection. Methods We conducted a descriptive and retrospective study between May 2020 and April 2022. In order to give full play to the efficacy of direct-acting antivirals (DAAs), we established a referral process for HCV patients with DAAs. Doctors prescribed DAAs for HCV-infected outpatients, and then transferred them to the outpatient clinic managed by pharmacists. Pharmacists cooperated to complete the pharmaceutical monitoring of DAAs treatment for patients. The pharmacist conducted a comprehensive evaluation of the patient's medication and developed planned intervention measures based on identified DRPs. Results A total of 473 eligible patients participated in 851 pharmaceutical care. A total of 518 DRPs were identified (an average of 1.1 per patient). Treatment effectiveness (48.8%) was the most common DRP. The most commonly recommended intervention was changing the drug (18.3%). There were 97.1% patients accepting the interventions and 93.05% patients completely implemented. The overall sustained virologic response at week 12 posttreatment (SVR12) rate was 98.5% (466/473). The most cost-effective treatment was selected in 98.7% of patients. Conclusions We confirmed that pharmacists had a valuable role to perform pharmacy services for HCV-infected outpatients. The intervention of pharmacists is effective in solving the DRPs and saving drug costs.

Publisher

Research Square Platform LLC

Reference32 articles.

1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021.

2. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study;Polaris Observatory HCV;Lancet Gastroenterol Hepatol,2022

3. [Guidelines for the prevention and treatment of hepatitis C (2019 version)];Chinese Society of Hepatology; Chinese Society of Infectious Diseases, Chinese Medical Association;Zhonghua Gan Zang Bing Za Zhi,2019

4. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018;European Association for the Study of the Liver;J Hepatol,2018

5. The National Healthcare Secruity Adminstration.The National Medical Insurance Administration and the Ministry of Human Resources and Social Security issued the list of drugs for entry into the National Medical insurance negotiation in 2019. 2019. Accessed November 28, 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3